The latest price target for Citius Oncology (NASDAQ:CTOR) was reported by Maxim Group on November 27, 2024. The analyst firm set a price target for $3.00 expecting CTOR to rise to within 12 months (a possible 150.02% upside). 2 analyst firms have reported ratings in the last year.

The latest analyst rating for Citius Oncology (NASDAQ:CTOR) was provided by Maxim Group, and Citius Oncology initiated their buy rating.

There is no last upgrade for Citius Oncology

There is no last downgrade for Citius Oncology.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Citius Oncology, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Citius Oncology was filed on November 27, 2024 so you should expect the next rating to be made available sometime around November 27, 2025.

While ratings are subjective and will change, the latest Citius Oncology (CTOR) rating was a initiated with a price target of $0.00 to $3.00. The current price Citius Oncology (CTOR) is trading at is $1.20, which is within the analyst’s predicted range.